Fate Therapeutics (id:6524 FATE)
2.29 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 7:49:02 PM)
Exchange closed, opens in 1 day 13 hours
About Fate Therapeutics
Market Capitalization 260.82M
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| Headquarters (address) |
12278 Scripps Summit Drive San Diego 92131 CA United States |
| Phone | 858 875 1800 |
| Website | https://www.fatetherapeutics.com |
| Employees | 181 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | FATE |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.96 - 8.83 |
| Market Capitalization | 260.82M |
| P/E trailing | -1.40 |
| P/E forward | -1.36 |
| Price/Sale | 19.40 |
| Price/Book | 0.720 |
| Beta | 1.88 |
| EPS | -1.64 |
| EPS United States (ID:6, base:3403) | 24.22 |